The current status of HBOC management in 14 Asian countries, including genetic counselling/testing uptakes and clinical management options, was reviewed. We analysed how economic factors, healthcare and legal frameworks, and cultural issues affect the genetic service availability in Asia. Results: In 2012, only an estimated 4,000 breast cancer cases from 14 Asian countries have benefited from genetic services. Genetic testing costs and the absence of their adoption into national healthcare systems are the main economic barriers for approaching genetic services. Training programmes, regional accredited laboratories and healthcare professionals are not readily available in most of the 54 studied countries. A lack of legal frameworks against genetic discrimination and a lack of public awareness of cancer risk assessment also provide challenges to HBOC management in Asia. Conclusions: The Asian BRCA Consortium reports the current disparities in genetic services for HBOC in Asia and urges the policy makers, healthcare sectors and researchers to address the limitations in HBOC management.
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Background
Worldwide and in Asia, breast cancer is the most common cancer among women, and the incidence and mortality are expected to increase by 50% between 2002 and 2020. These rising cancer rates will be the greatest in developing countries, particularly in Asia where incidence and mortality were estimated to be 29.1 and 10.2 per 100,000 (age-standardised rates), respectively (Globocan 2012; http://globocan.iarc.fr). It is estimated that 2-4% of breast cancer cases occur in women with an alteration in the breast cancer susceptibility genes BRCA1 and BRCA2 [1] [2] [3] [4] [5] , and the prevalence of mutations appears similar in Caucasian and Asian populations [6] [7] [8] . However, although up to 60% of the world's population are Asians, there remain major gaps in genetic counselling and genetic testing in Asia, and it is estimated that less than 5% of the BRCA1 and BRCA2 carriers identified are from Asia [9] .
In order to share knowledge, improve the quality of clinical services and conduct research on hereditary breast and ovarian cancer (HBOC) in Asia, we have established the Asian BRCA (ABRCA) Consortium in October 2011. To date, the Consortium has members from 14 Asian countries and welcomes new members with a shared vision of collaborating for research in Asia [10] [11] [12] . In this report, the ABRCA Consortium members describe the status of genetic counselling, genetic testing and risk management in these 14 countries and highlight the need for action from governments, healthcare providers and researchers in order to address the disparities in care in HBOC.
Methods
The ABRCA Consortium held its second meeting in Kuala Lumpur, Malaysia, in August 2012 and has since had regular annual meetings in Hong Kong, Korea and Japan. Previous meetings have brought together experts from initially 10 Asian countries, namely Korea, Japan, Malaysia, Singapore, Hong Kong, China, Indonesia, Thailand, the Philippines and India, and subsequently further inputs were received from Bangladesh, Pakistan, Taiwan and Vietnam. To provide an organised framework for consensus development and research, three working groups (mutation spectrum including variants, penetrance and modifiers of risk, and clinical management) were organised. For the purpose of this report from the clinical management working group, each country representative met and discussed various practical aspects of familial cancer management in Asian countries and agreed on the structure and content of the report resulting from the meeting. In addition, a literature search was conducted to identify and catalogue all indexed reports of studies in BRCA1 and BRCA2 undertaken in Asian countries between 1994 and 2012, using PubMed as the searched database.
Results

Present Status of Accessibility to Genetic Counselling and Genetic Testing in 14 Asian Countries
Based on the information from the ABRCA Consortium, there are differences in the accessibility to genetic counselling and genetic testing within the 14 studied Asian countries, and also in comparison to Western countries.
Notably, although healthcare resources usually correspond directly to World Bank economic stratification or organisation of healthcare delivery, availability of and payment for genetic counselling and genetic testing do not always correspond in a similar manner ( table 1 ) . For example, despite living in high-resource countries, patients in Singapore, Japan and Taiwan [gross national income (GNI) per capita of USD 49,710, 47,870 and 21,042, respectively] pay out-of-pocket for genetic counselling and genetic testing in 2012. By contrast, in South Korea (GNI per capita: USD 22,670), a national programme for genetic counselling and genetic testing has become available through the national healthcare system since 2007. As a result of governmental financial support, the genetic testing acceptance rate for referred probands has greatly increased from 64 to 85% after the introduction of reimbursement from the National Healthcare Insurance. In Hong Kong, Malaysia and Pakistan, genetic testing is largely funded through research and charitable funding, and uptake rates of self-paid testing are comparatively lower than funded testing in Hong Kong, whereas in Thailand, Indonesia, the Philippines, Vietnam, Bangladesh and 3 centres in China, genetic testing has largely stopped at the end of the research studies. Taken together, these data suggest that, in addition to economic factors, the healthcare system, legal system and cultural issues should all be considered in the assessment of disparities in the availability and uptake of genetic counselling and testing. For most of the studied countries, funding and financial resources are the major issues that limit the accessibility to genetic counselling and testing. With the presence of governmental financial support, such as in South Korea, the uptake rates for genetic services are much higher. In contrast, for some developing Asian countries, such as Malaysia, cultural factors play an important part in deciding on the uptake of genetic testing.
The net result is that in 2012, there were overall 560,000 breast cancer patients in 14 Asian countries (Globocan 2012 and local authority data), of whom less than 1% may benefit from genetic counselling. The proportions of genetic testing uptake to breast cancer incidence vary in different countries, with the highest proportion of 7.7% being reported in Korea. As shown in online supplementary table S1 (see www.karger.com/doi/10.1159/000441714), most of the data from each country were obtained from 1-2 centres (except Korea), only around 4,000 individuals were offered genetic counselling and 3,200 were tested. Of these, the vast majority (more than 40%) were from Korea.
Health System Barriers to Genetic Counselling and Genetic Testing
The absence of genetic counselling and genetic testing services in most parts of Asia is the main reason for disparity. Appropriate genetic counselling, which is crucial to ensure the protection of the patient's rights, needs welltrained healthcare professionals (particularly genetic counsellors) and clear clinical referral routes. Unfortunately, trained personnel, training programmes and formal accreditation processes for clinical and laboratory services are scarce in Asia ( table 2 ) . In Japan, genetic counselling training programmes have been established and implemented since 2003. In 2005, these 10 pro- b Health expenditure per capita (current USD): the total health expenditure is the sum of public and private health expenditures as a ratio of the total population; it covers the provision of health services (preventive and curative), family planning activities, nutrition activities and emergency aid designated for health but does not include provision of water and sanitation; data are in current USD (source: World Health Organisation National Health Account database).
c 2011 (source: Food and Health Bureau, Hong Kong Government).
grammes were accredited by the Japanese Board of Genetic Counselling, a joint effort of two genetics societies, the Japan Society of Human Genetics and the Japanese Society for Genetic Counselling. As of October 2013, approximately 150 certified genetic counsellors have been trained in Japan. In Korea, regional referral centres have started training programmes for genetic counsellors since 2011, and, in addition, animation-based educational tools have been developed for patients. For other Asian countries, genetic counselling may be performed by the doctors, or doctor-trained nurses, and healthcare workers through clinical work, with some having attended certificate courses available in the West. Regional laboratory testing services, adequate funding and trained personnel are available in only 6 of the 14 Asian countries in this report, suggesting that geographical and economic access to these services also contribute to the inequity in the distribution of genetic services in Asia.
Legal System Barriers to Genetic Counselling and Genetic Testing
Although testing cost is a common and significant barrier to genetic testing, the lack of legal protection against genetic discrimination is also a major issue. In the US, the Genetic Information Non-Discrimination Act was established in 2007 and prohibits health insurers from requesting or requiring genetic information on individuals and their family members, or using it for decisions on insurance and employment. To date, in Asia, only Korea has established a similar legal protection since 2005.
Patient-Related Barriers to Genetic Counselling and Genetic Testing
Given that disclosure of genetic information is dependent on social, cultural, religious and familial factors and that these variables are distinct in Asian compared to Caucasian populations, to date, however, studies in these areas in Asia are still lacking. There have been data showing that 94, 66 and 64% of probands informed at least one first-degree relative in Hong Kong, Malaysia and India, respectively ( table 3 ) . Overall, few relatives have been recruited for genetic counselling and testing in Asian countries.
Management of Affected and Unaffected BRCA Carriers BRCA1 and BRCA2 carriers have a significantly higher risk for breast and ovarian cancer, and breast cancer patients have a significantly increased risk for contralateral breast cancer. The majority of Asian countries have 
Discussion
It is noticeable that genetic service accessibility for HBOC patients in Asia is far limited when compared to Western countries and also varies among the ABRCA Consortium groups. Findings from high-resource countries such as the USA, UK and Australia also showed great variations in genetic testing uptake rates between different studies, ranging from 25 to 96% [13, 14] , and uptake in primary care is variable. In Asia, the shared view among the ABRCA groups is that disparities in access to genetic counselling and genetic testing are largely attributable to the lack of access to appropriately trained laboratory and healthcare professionals, and lack of funding for laboratory and clinical services, which leads to particularly large disparities when combined with limited regulatory framework for genetic testing laboratory accreditation and prevention of genetic discrimination, and Asian socio-cultural beliefs of families and genetics.
To date, the cost of genetic testing and the lack of adoption into national healthcare systems are major barriers to genetic counselling and genetic testing in Asian countries, with the exception of South Korea. Although inadequate, the funding of genetic counselling and genetic testing using research grants and charitable funding, such as that in Hong Kong, India, Malaysia, Pakistan and Thailand, continues to provide interim services that help to bridge the disparity in care. It is hoped that as the cost of sequencing becomes cheaper through the development of new sequencing technologies, this will enable 58 more regional laboratory services to be established. Notably, training programmes for genetic counsellors have been established in India, Japan, Korea, the Philippines and Taiwan; such programmes are also needed in other countries to address their genetic counselling service needs, particularly in recognition of the multicultural, multireligious and multilingual settings in Asia. Where possible, genetic counselling and genetic testing should be centralised with multidisciplinary expertise to avoid system fragmentation and to help health policy to be adopted in a more consistent manner. It is also very important that centres of excellence and accredited laboratories for quality control are established to define a standard of care for each country. However, these must be balanced by outreach into rural areas to cover the large geographical area in Asia.
The estimated breast cancer incidence for Asian populations [age-standardised rate (ASR): 29.1 per 100,000; Globocan 2012] was lower than the corresponding estimates for Western populations in Europe (ASR: 69.9 per 100,000) and North America (ASR: 91.6 per 100,000).
However, very little is known about the breast cancer penetrance for Asian BRCA1 and BRCA2 carriers due to the short establishment of genetic testing programmes, short follow-up time and smaller cohort sizes in Asian studies. In Korea, the recently estimated penetrance for BRCA1 and BRCA2 carriers up to the age of 70 years was 49 and 35%, respectively [15] , and the penetrance data are still missing in other Asian countries. Also, there is insufficient family history information in some Asian countries such as China, where birth control policy and population migration leads to smaller family sizes. As a result of these limitations, risk assessment models specific for Asian BRCA1/2 mutations are under development, and most Asian countries still follow the international guidelines for prevention and surveillance strategies.
Throughout Asia, there is a need to increase the awareness of the promises and pitfalls of genetics not only among medical personnel but also among patients and the community. Individual centres in Asia have organised community-based awareness programmes to promote the importance of genetic testing, yet there is insuf- not offered seldom offered offered strongly recommended Vietnam no structured guidelines MMG n/a n/a n/a n/a Pakistan USA NCCN guidelines annual MMG/US/MRI (alternating 6-monthly) offered both offered offered offered Bangladesh no structured guidelines n/a n/a n/a n/a n/a RRSO = Risk-reducing salpingo-oophorectomy; MMG = mammography; US = ultrasound; n/a = not available.
59 ficient education at the population level. There is also a need to persuade the governmental bodies to provide protection against genetic discrimination, which is one of the major factors deterring patients and families from undertaking genetic testing. Given the religious, social and cultural beliefs of different Asian populations, which are more conservative when compared to the West, social stigmata including the perception of cancer and genetic variations remain an annoying barrier for Asians when addressing breast cancer and genetic risks. Asian Americans have been reported to have lower acceptance rates for breast cancer screening and genetic testing and were less likely to inform relatives of genetic testing results or to pursue family testing [16] . However, little is known about the effects of breast cancer-related stigmata in Asian countries. Undoubtedly, more input is needed to raise the understanding of breast cancer and genetic risks and help remove cancer-related social stigmata.
Conclusions
Twenty years after the complete sequencing of the BRCA1 gene, in Asia, major challenges in catching up with the genomic revolution remain, although genetic testing has become the standard of care in the West and with an increasing amount of interest groups, such as the BRCA Challenge and the CIMBA Consortium, taking the lead in connecting the genomic bases of breast cancer to clinical application in order to improve outcomes and prevention strategies of the disease. Particularly in lowincome countries, we face many challenges including few advanced genetics laboratories, inadequate healthcare professionals, non-existent legal protection against genetic discrimination and inadequate funding to support research and clinical services. While these must be balanced by competing financial needs, the ABRCA Consortium is hoping to work towards ensuring that disparities in care are reduced as much as possible. The ABRCA Consortium will be periodically held; it will share the status of genetic counselling, genetic testing and risk management in Asia and will appeal for action from governments and healthcare providers in order to address the disparities for HBOC, so that more of these high-risk families can benefit.
